Regulatory FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program FDAThe U.S.RegulatoryGene TherapyRead full story pharminent April 23, 2026 (Last updated: April 24, 2026) FDA The U.S. RegulatoryGene TherapyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug CoverageNext: FDA approves Regeneron’s hearing loss gene therapy Related Stories Regulatory Replimune gets early August decision date for twice-rejected melanoma drug pharminent June 26, 2026 Regulatory Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use pharminent June 25, 2026 Regulatory MSD’s Keytruda-Padcev combo secures EC approval for MIBC pharminent June 25, 2026
